INDUCTION OF INTERSTITIAL PNEUMONITIS DURING INTERFERON TREATMENT FOR CHRONIC HEPATITIS-C

被引：34

作者：

MORIYA, K ^{[1
]}

YASUDA, K ^{[1
]}

KOIKE, K ^{[1
]}

ICHINOSE, Y ^{[1
]}

YOTSUYANAGI, H ^{[1
]}

KUROKAWA, K ^{[1
]}

IINO, S ^{[1
]}

机构：

[1] UNIV TOKYO,DEPT INTERNAL MED 1,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN

来源：

JOURNAL OF GASTROENTEROLOGY | 1994年 / 29卷 / 04期

关键词：

INTERFERON; INTERSTITIAL PNEUMONITIS; SIDE EFFECTS;

D O I：

10.1007/BF02361253

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

A 48-year-old woman developed interstitial pneumonitis while receiving interferon treatment for chronic hepatitis C. Laboratory studies prior to treatment showed elevated serum alanine aminotransferase levels, but chest X-rays and physical examination revealed no abnormalities suggestive of interstitial pneumonitis. At the 9th week of interferon treatment (total dose, 380 MU of recombinant interferon-alpha, without other medications), the patient began to complain of cough and exertional dyspnea. A chest X-ray film revealed diffuse reticulo-nodular shadows in bilateral lung fields, suggesting a diagnosis of interstitial pneumonitis. A marked increase in lymphocyte count was observed in bronchoalveolar lavage fluid and a diagnosis of interstitial pneumonitis was made as a result of transbronchial lung biopsy. Her clinical symptoms and abnormal lung shadows were reversible, improving within a month of the discontinuation of interferon, and disappearing promptly after exogenous corticosteroid was instituted. This may be the first case of drug-induced interstitial pneumonitis occurring during the course of treatment with interferon alone. We should be aware of the possibility of interstitial pneumonitis developing during treatment of chronic hepatitis C with interferon.

引用

页码：514 / 517

页数：4

共 13 条

[1]

Choo Q.L., Kuo G., Weiner A.J., Et al., Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome, Science, 244, pp. 359-362, (1989)

[2]

Hosoda K., Omata M., Yokosuka O., Et al., Non-A, Non-B chronic hepatitis is chronic hepatitis C: A sensitive assay for detection of hepatitis C virus RNA in the liver, Hepatology, 15, pp. 777-781, (1992)

[3]

Davis G.L., Balart L.A., Schiffer E.R., Et al., The Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis with recombinant interferon alpha: A multicenter randomized, controlled trial, N Engl J Med, 321, pp. 1501-1506, (1989)

[4]

Di Bisceglie A.M., Martin P., Kassianides C., Et al., Recombinant interferon alpha therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial, N Engl J Med, 321, pp. 1506-1510, (1989)

[5]

Iino S., Hino K., Kondo T., Et al., Interferon therapy for non-A, non-B chronic hepatitis, Gastroenterol Jpn, 26, pp. 224-229, (1991)

[6]

Conlon K.C., Urba W.J., Smith J.W., Et al., Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy, Cancer, 65, pp. 2237-2242, (1900)

[7]

Schultz M., Muller R., von zur Muhlen A., Et al., Induction of hyperthyroidism by interferon alpha-2b (letter), Lancet, 2, (1989)

[8]

Papo T., Marcellin P., Bernau J., Et al., Autoimmune chronic hepatitis exacerbated by alpha-interferon, Annals of Internal Medicine, 116, pp. 51-53, (1992)

[9]

Allen D., Cooper J.R., White D.A., Et al., Drug-induced pulmonary disease, Am Rev Respir Dis, 133, pp. 321-340, (1986)

[10]

Crystal R.G., Bitterman R.B., Rennard S.I., Et al., Interstitial lung disease of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts), N Engl J Med, 310, pp. 154-166, (1984)

← 1 2 →